BAQSIMI Adverse Reactions in Adult Patients
Adverse reactions (%) in adult Type 1 and Type 2 diabetes patients with an incidence ≥5%
| Adverse Reactions | IGBC Type 1 and Type 2 diabetes BAQSIMI 3 mg (n=83) % | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % |
|---|---|---|
| Adverse Reactions Eye disorders | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % |
| Adverse Reactions Lacrimation increased | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 8.4 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 1.2 |
| Adverse Reactions Gastrointestinal disorders | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % |
| Adverse Reactions Nausea | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 21.7 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 26.8 |
| Adverse Reactions Vomiting | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 15.7 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 11.0 |
| Adverse Reactions General disorders and administration site conditions | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % |
| Adverse Reactions Fatigue | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 8.4 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 8.5 |
| Adverse Reactions Nervous system disorders | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % |
| Adverse Reactions Headache | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 20.5 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 8.5 |
| Adverse Reactions Respiratory, thoracic, and mediastinal disorders | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % |
| Adverse Reactions Nasal discomfort | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 9.6 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 0 |
| Adverse Reactions Nasal congestion | IGBC Type 1 & Type 2 diabetes BAQSIMI 3 mg (n=83) % 8.4 | IGBC Type 1 and Type 2 diabetes INJECTABLE GLUCAGON weight based (n=82) % 1.2 |